XML 91 R54.htm IDEA: XBRL DOCUMENT v2.3.0.15
Fair Value Measurements (Details Textuals) (USD $)
In Millions, unless otherwise specified
3 Months Ended9 Months Ended
Sep. 30, 2011
Dec. 31, 2010
Sep. 06, 2011
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH [Member]
Sep. 06, 2011
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH [Member]
Other Liabilities Current [Member]
Sep. 06, 2011
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH [Member]
Other Liabilities Non Current [Member]
Sep. 30, 2011
Biogen Idec International Neuroscience GmbH [Member]
Sep. 30, 2011
Biogen Idec International Neuroscience GmbH [Member]
Dec. 17, 2011
Biogen Idec International Neuroscience GmbH [Member]
Sep. 30, 2011
Biogen Idec International Neuroscience GmbH [Member]
Other Liabilities Current [Member]
Sep. 30, 2011
Biogen Idec International Neuroscience GmbH [Member]
Other Liabilities Non Current [Member]
Sep. 30, 2011
6.0% Senior Notes due 2013 [Member]
Sep. 30, 2011
6.875% Senior Notes due 2018 [Member]
Investments and Acquisitions at Fair Value            
Net cash outflow to determine valuations  $ 42.5  $ 395.0$ 395.0     
Discount rate used for net cash outflow projections for fair value measurement  3.20%  5.30%5.30%     
Fair value adjustment of contingent consideration     2.55.9     
Fair Value Measurements (Additional Textuals) [Abstract]            
Contingent consideration  $ 38.8$ 4.0$ 34.8$ 87.1$ 87.1$ 81.2$ 5.0$ 82.1  
Fair Value, Option, Quantitative Disclosures [Line Items]            
Interest rate on Senior Notes          6.00%6.875%
Fair Value Measurements (Textuals) [Abstract]            
Venture capital investments as a percentage of our total assetsapproximately 0.3% of total assetsapproximately 0.3% of total assets